FHIT Gene, Smoking, and Cervical Cancer

OncologyONCOLOGY Vol 14 No 3
Volume 14
Issue 3

At the recent annual meeting of the Society of Gynecologic Oncologists (SGO), researchers announced findings suggesting that the putative tumor-suppressor gene-the fragile histidine triad (FHIT) gene-may be central to the development of

At the recent annual meeting of the Society of Gynecologic Oncologists (SGO), researchers announced findings suggesting that the putative tumor-suppressor gene—the fragile histidine triad (FHIT) gene—may be central to the development of cervical cancer. The gene appears to be particularly susceptible to carcinogens from cigarette smoke, and cigarette smoking is an epidemiologic risk factor for cervical cancer.

Cigarette smoke carcinogens have been found in cervical mucus. The FHIT gene is frequently altered in smoking-associated lung cancer and is located on chromosome 3p14.2, surrounding FRA3B, one of the most fragile sites of the human genome and a known human papillomavirus (HPV) integration site.

The human papilloma virus is detected in more than 90% of all squamous cell carcinomas of the uterine cervix, and is thought to be integral to the development of cervical cancer. However, the reported annual rates of HPV infection are over 1,000 times higher than the annual incidence of cervical cancer, and at least 90% of HPV infections resolve spontaneously. Therefore, other carcinogenic cofactors are important in the evolution of cervical cancer, one of which is cigarette smoking.

Cigarette Smoking and the FHIT Gene

The study was conducted by Christine H. Holschneider,MD, Rae Lynn Baldwin, MD, Jeffrey S. Epstein, MS, and Beth Y. Karlan, MD, of Cedars Sinai Medical Center and the University of California, Los Angeles; and Juan C. Felix, MD, University of Southern California. The researchers hypothesized that cigarette smoking–associated cervical cancer may share certain pathogenetic features with other tobacco-associated malignancies. Studies of lung cancers and premalignant pulmonary lesions have demonstrated a strong association between cigarette smoking and alterations in the FHIT gene.

The researchers reviewed archival tissues of 37 patients (17 smokers, 20 nonsmokers) who had undergone radical hysterectomy for squamous cell carcinoma of the cervix. Data on patient age, race, smoking habits, tumor grade, and date of radical hysterectomy were extracted from medical records. Patients were only included in the study if their smoking status was clearly documented in at least two different sites in the hospital chart, such as the admission records, consultations, or anesthesia notes. From each specimen block, contiguous sections were prepared and used for immunohistochemistry and laser capture microdissection.

Study Results

The human papillomavirus was detected in 92% of the tumors, 88% of dysplasias, and 85% of nondysplastic epithelia adjacent to the tumor. There was no significant difference in the HPV status of smokers vs nonsmokers. However, a reduction of FHIT protein expression, as well as homozygous deletions at the FHIT gene locus, occurred significantly more frequently in the tumors of smokers vs nonsmokers. The researchers are currently investigating whether FHIT is a potential genetic link between cigarette smoking and cervical cancer.

Articles in this issue

Comparative Economic Analysis of the Treatment of Relapsed Low-Grade B-Cell Non-Hodgkin’s Lymphoma (NHL) in France Using CHOP, Fludarabine, or Rituximab
FHIT Gene, Smoking, and Cervical Cancer
Final Report on the Safety and Efficacy of Retreatment With Rituximab for Patients With Non-Hodgkins Lymphoma
Prospective, Randomized, Controlled Study of Zevalin Radioimmunotherapy Compared to Rituximab Immunotherapy for B-Cell, Non-Hodgkins Lymphoma: Interim Results
IOM Medical Error Estimates Questioned, But Legislation Considered
Less Toxic Therapies for Hodgkin’s Disease May Reduce Secondary Cancers
Preserving Fertility in Young Women With Ovarian Cancer Does Not Decrease Survival
Iodine-131 Tositumomab for Patients With Transformed, Low-Grade Non-Hodgkin’s Lymphoma: Overall Clinical Trial Experience
Survival Rates Significantly Worse For African-Americans With Endometrial Cancer
Rituximab Has Significant Activity in Patients With Chronic Lymphocytic Leukemia
Responders to Rituximab Show Continued Tumor Regression Over Time and a Progression-Free Survival That Correlates With Response Classification
PhRMA Criticizes FDA’s Proposed Rule on Antibiotic Approvals
Phase II Study of Rituximab in Combination With CHOP in Patients With Previously Untreated Intermediate- or High-Grade Non-Hodgkin’s Lymphoma
New Antibiotic Effective in Treating Gram-Positive Bacteremia
Reduced-Dose Zevalin Radioimmunotherapy for Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma Patients With Preexisting Thrombocytopenia: Report of Interim Results of a Phase II Trial
Related Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Despite the addition of a TIGIT inhibitor to a checkpoint inhibitor resulting in high levels of safety, there is no future for that combination alone, according to Ritu Salani, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Related Content